Press Releases for IDEV

Press Releases
Endo Pharmaceuticals Announces Successful Completion of Tender Offer for Indevus Pharmaceuticals
Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
Burns & Levinson Guides Indevus Through Significant Pharmaceutical Transaction
Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals
Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
Zacks Analyst Blog Highlights: Sohu.Com, Inc., Priceline.Com, Dollar Financial Corp., Indevus Pharmaceuticals and Endo Pharmaceuticals.
BenchmarkJournal.Com (Complimentary) Analyst Review for IDEV, AMED, ENDP and CIEN
Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Indevus Pharmaceuticals to Announce Fiscal 2008 Financial Results on Tuesday, November 25, 2008
Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
Indevus Announces Initiation of Phase III Clinical Trial of Octreotide Implant for Acromegaly
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
Indevus and FDA Agree on Path Forward for NEBIDO(R)
Indevus Pharmaceuticals Scheduled to Present at 2008 UBS Global Life Sciences Conference
Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
BeaconEquity.com Issues TraderNotes on Active Stocks: WWAT, UCBH, PMTI, XMSR, IDEV, F, BUSE, HYGS
Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Indevus Announces Management Changes
BellwetherReport.com Analyst Report on IDEV, TIBX, SQNM and PMCS
Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
Indevus Pharmaceuticals Licenses Canadian Rights for SANCTURA XR(TM) to Allergan, Inc. - May 27 2008 1:01AM
Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association - May 27 2008 12:59AM
Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences - May 27 2008 12:54AM
Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty - Jun 1 2008 10:53PM
Indevus Pharmaceuticals Announces Second Quarter Fiscal 2008 Financial Results
Indevus to Announce Second Quarter Fiscal 2008 Financial Results on Wednesday, April 30, 2008
Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation